NASDAQ$TCRX
Tscan Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
TScan Therapeutics reported financial results for the third quarter ended September 30, 2023.
TScan Therapeutics reported revenue of $3.9 million and a net loss of $23.0 million for the third quarter ended September 30, 2023. The company ended the quarter with $215.4 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2026.
- TScan will present initial data from heme malignancies Phase 1 trial at the 65th ASH Annual Meeting and Exposition.
- The company announced recent FDA clearance of IND for TSC-203-A0201 targeting PRAME.
- TScan presented six posters at the SITC 38th Annual Meeting, highlighting solid tumor Phase 1 trial design and addition of melanoma-associated antigen C2 (MAGE-C2) to ImmunoBank.
- TScan ended Q3 with cash, cash equivalents, and marketable securities of $215.4 million, funding operations into 2026.
Headline financials
Revenue & EPS history
Tscan Therapeutics · Revenue · Quarterly
$3.89M
Revenue by segment
Tscan Therapeutics · $3.89M total across 1 segment · Q3 2023
- Collaboration & License$3.89M—100.0%
Forward guidance
TScan anticipates several clinical milestones for its heme malignancies and solid tumor programs. The company expects to reach the recommended Phase 2 dose for both TSC-100 and TSC-101 and report interim clinical data for the heme program by the end of 2023. For the solid tumor program, TScan anticipates further expansion of the ImmunoBank with IND filings for two additional TCR-Ts by year-end 2023 and plans to initiate a Phase 1 solid tumor clinical study and enroll the first patient by year-end 2023.
Tailwinds
- Reach the recommended Phase 2 dose for both TSC-100 and TSC-101 by the end of 2023.
- Report interim clinical data for the heme program by the end of 2023.
- Expand the ImmunoBank with IND filings for two additional TCR-Ts by year-end 2023.
- Initiate Phase 1 solid tumor clinical study and enroll the first patient by year-end 2023.
- Report initial multiplexed therapy data for its first combinations of TCR-Ts under T-Plex, as well as response data for singleplex cohorts, in 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+1.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-5.7%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+32.4%
Q1 2023
Best reaction
-18.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | -3.3% | -18.9% | |
| Q4 2025 | +4.9% | +19.8% | -2.4% | |
| Q3 2025 | +0.8% | -20.5% | -17.2% | |
| Q2 2025 | +3.1% | +11.8% | +14.9% | |
| Q1 2025 | -4.6% | +0.8% | +18.3% | |
| Q4 2024 | +2.6% | +7.7% | -7.1% | |
| Q3 2024 | -7.9% | -22.6% | -47.0% | |
| Q2 2024 | -1.0% | -3.0% | -3.9% | |
| Q1 2024 | +16.3% | +16.2% | +14.9% | |
| Q4 2023 | +1.6% | -6.7% | +0.9% | |
| Q3 2023 | +3.0% | +14.9% | +50.8% | |
| Q2 2023 | -4.2% | -2.3% | +12.1% | |
| Q1 2023 | +32.4% | +18.5% | -14.4% | |
| Q4 2022 | -8.5% | -23.0% | -33.3% | |
| Q3 2022 | -0.4% | +3.9% | -20.6% | |
| Q2 2022 | -10.8% | -18.8% | -20.5% | |
| Q1 2022 | +10.6% | +38.3% | +80.0% | |
| Q4 2021 | +7.8% | -1.6% | -37.8% | |
| Q3 2021 | +2.2% | -4.4% | -28.0% | |
| Q2 2021 | -18.2% | -21.7% | -53.7% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro